83 related articles for article (PubMed ID: 31526755)
1. LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy.
Scuoppo C; Zha S
Cancer Cell; 2019 Sep; 36(3):211-212. PubMed ID: 31526755
[TBL] [Abstract][Full Text] [Related]
2. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma.
Wu J; Shi C; Li H; Song W; Huang S; Zhang J; Li W; Li Z; Zhang M
BMC Med; 2023 Jul; 21(1):253. PubMed ID: 37442994
[TBL] [Abstract][Full Text] [Related]
4. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
5. LIM Domain Only 2 Regulates Endothelial Proliferation, Angiogenesis, and Tissue Regeneration.
Meng S; Matrone G; Lv J; Chen K; Wong WT; Cooke JP
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792641
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract.
Chapman-Fredricks J; Younes SF; Fan YS; Sandoval-Sus JD; Natkunam Y; Lossos IS
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):200-4. PubMed ID: 22914613
[TBL] [Abstract][Full Text] [Related]
7. A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma.
Liu Y; Bian T; Zhang Y; Zheng Y; Zhang J; Zhou X; Xie J
Diagn Pathol; 2019 Sep; 14(1):100. PubMed ID: 31484540
[TBL] [Abstract][Full Text] [Related]
8. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
9. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
10. [Regulation of E-cadherin promoter activity by LMO2 impact on the progression and metastasis of prostate cancer].
Peng X; Ye Z; Gao Y
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2013 Sep; 29(5):385-9. PubMed ID: 24386807
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.
Miyashita K; Kitajima K; Goyama S; Kitamura T; Hara T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2310-2316. PubMed ID: 29278703
[TBL] [Abstract][Full Text] [Related]
12. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.
Liu Y; Wang Z; Huang D; Wu C; Li H; Zhang X; Meng B; Li Z; Zhu T; Yang S; Sun W
Oncotarget; 2017 Feb; 8(6):9513-9524. PubMed ID: 27880729
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of the role of LMO2 in human erythroid cells.
Inoue A; Fujiwara T; Okitsu Y; Katsuoka Y; Fukuhara N; Onishi Y; Ishizawa K; Harigae H
Exp Hematol; 2013 Dec; 41(12):1062-76.e1. PubMed ID: 24041784
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
15. LIM domain only 2 over-expression in prostate stromal cells facilitates prostate cancer progression through paracrine of Interleukin-11.
Jiang CY; Yu JJ; Ruan Y; Wang XH; Zhao W; Wang XJ; Zhu YP; Gao Y; Hao KY; Chen L; Han BM; Xia SJ; Zhao FJ
Oncotarget; 2016 May; 7(18):26247-58. PubMed ID: 27028859
[TBL] [Abstract][Full Text] [Related]
16. The LIM domain protein Lmo2 binds to AF6, a translocation partner of the MLL oncogene.
Bégay-Müller V; Ansieau S; Leutz A
FEBS Lett; 2002 Jun; 521(1-3):36-8. PubMed ID: 12067721
[TBL] [Abstract][Full Text] [Related]
17. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.
Goodings C; Tripathi R; Cleveland SM; Elliott N; Guo Y; Shyr Y; Davé UP
Leuk Res; 2015 Jan; 39(1):100-9. PubMed ID: 25499232
[TBL] [Abstract][Full Text] [Related]
18. The expression of LMO2 protein in acute B-cell and myeloid leukemia.
Cobanoglu U; Sonmez M; Ozbas HM; Erkut N; Can G
Hematology; 2010 Jun; 15(3):132-4. PubMed ID: 20557670
[TBL] [Abstract][Full Text] [Related]
19. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.
Kim SH; Kim EJ; Hitomi M; Oh SY; Jin X; Jeon HM; Beck S; Jin X; Kim JK; Park CG; Chang SY; Yin J; Kim T; Jeon YJ; Song J; Lim YC; Lathia JD; Nakano I; Kim H
Cell Death Differ; 2015 Sep; 22(9):1517-25. PubMed ID: 25721045
[TBL] [Abstract][Full Text] [Related]
20. LMO2 Enhances Lamellipodia/Filopodia Formation in Basal-Type Breast Cancer Cells by Mediating ARP3-Profilin1 Interaction.
Liu Y; Wu C; Zhu T; Sun W
Med Sci Monit; 2017 Feb; 23():695-703. PubMed ID: 28170369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
